Bausch + Lomb (NYSE:BLCO) Announces Earnings Results, Beats Estimates By $0.02 EPS

Bausch + Lomb (NYSE:BLCO) released its earnings results on Wednesday. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02, Zacks reports. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.34% and a negative net margin of 6.62%. Bausch + Lomb’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS. Bausch + Lomb updated its FY 2025 guidance to EPS.

Bausch + Lomb Stock Down 2.4 %

NYSE:BLCO opened at $15.92 on Friday. Bausch + Lomb has a 1 year low of $13.16 and a 1 year high of $21.69. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. The stock has a 50-day simple moving average of $17.42 and a 200-day simple moving average of $18.13.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BLCO. Bank of America dropped their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating for the company in a report on Thursday. Royal Bank of Canada decreased their price target on shares of Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday. Citigroup lowered Bausch + Lomb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Thursday. Finally, Morgan Stanley cut Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price for the company. in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $19.83.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.